Patents by Inventor Costas A. Lyssiotis

Costas A. Lyssiotis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
    Patent number: 10837015
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 17, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • TARGETING THE GLUTAMINE TO PYRUVATE PATHWAY FOR TREATMENT OF ONCOGENIC KRAS-ASSOCIATED CANCER
    Publication number: 20190136238
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Application
    Filed: October 12, 2018
    Publication date: May 9, 2019
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
    Patent number: 10138479
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: November 27, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alec Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Methods for diagnosing and treating oncogenic kras-associated cancer
    Patent number: 9745631
    Abstract: Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: August 29, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Ronald A. DePinho, Lewis Cantley, Alec C. Kimmelman, Haoqiang Ying, Costas A. Lyssiotis
  • METHODS FOR DIAGNOSING AND TREATING ONCOGENIC KRAS-ASSOCIATED CANCER
    Publication number: 20150126580
    Abstract: Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.
    Type: Application
    Filed: December 19, 2012
    Publication date: May 7, 2015
    Inventors: Ronald A. DePinho, Lewis Cantley, Alec C. Kimmelman, Haoqiang Ying, Costas A. Lyssiotis
  • TARGETING THE GLUTAMINE TO PYRUVATE PATHWAY FOR TREATMENT OF ONCOGENIC KRAS-ASSOCIATED CANCER
    Publication number: 20150110773
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Application
    Filed: May 23, 2013
    Publication date: April 23, 2015
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis